Corvus Pharmaceuticals was named a top Mizuho pick for January 2026, with the firm noting that the company currently trades at a valuation discount compared to other atopic dermatitis biotech peers—a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback